Drugs / Biapenem
Biapenem
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01772836 | Mar 2013 | bacterial infectious disease | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Completed | No outcome recorded |
| Phase 1 | NCT01702649 | Aug → Nov 2012 | bacterial infectious disease | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biapenem | “RPX2003 (Biapenem)” NCT01702649 ↗ |
| Known as | CL 186,815 | ChEMBL registry synonym — accepted as the source's own label CHEMBL285347 ↗ |
| Known as | L-627 | ChEMBL registry synonym — accepted as the source's own label CHEMBL285347 ↗ |
| Known as | LJ C10,627 | ChEMBL registry synonym — accepted as the source's own label CHEMBL285347 ↗ |
| Known as | Omegacin | ChEMBL registry synonym — accepted as the source's own label CHEMBL285347 ↗ |
| Known as | RPX2003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01702649 ↗ |
| Modality | Small molecule | — CHEMBL285347 ↗ |
| Route | Intravenous | “Intravenous RPX2003” NCT01702649 ↗ |